A survey of allied think tanks summarizes what 23 nations and the EU are doing best when it comes to innovation policy, and where there are the greatest opportunities to improve. In many cases, the successes can serve as model policies for other countries to adopt.
Our studies, projects and policy recommendations identify the risks and opportunities for our economy and our society. Here you'll find an overview of our reports.
A Declaration of Mutual Interest in Trade and Globalization for the Benefit of All Peoples and Nations
Thu, 04/13/2017
This report assesses 56 countries on how their economic and trade policies contribute to and detract from innovation globally.
Information Technology and Innovation FoundationWed, 01/20/2016
This blueprint aims to inform European institutions on the state of innovation in three sectors (Digital, Healthcare, and Energy & Mobility).
I-Com Tue, 02/18/2020
Recent Reports
This blueprint aims to inform European institutions on the state of innovation in three sectors (Digital, Healthcare, and Energy & Mobility).
The United States, the EU, and Japan must band together in stronger trilateral partnership to pressure China into rolling back the mercantilist trade practices it uses to grow advanced, innovation-driven industries.
This blueprint aims to inform European institutions on the state of innovation in three sectors (Digital, Healthcare, and Energy & Mobility).
Countries that value an open, competitive digital economy should use surveys to improve quantitative analysis of cross-border data flows, because policymakers can’t effectively manage and address barriers to digital trade unless they can measure it.
The People’s Republic of China experienced a tremendous economic development within the last four decades. The strategies used by China for its own development, e.g. broad-based industry policy with forced technology transfer, are perceived as unfair not only in the US but to a large extent also in the EU.
Since the early 1990s, India's per capita income has grown at an average of 4% every year, which has lifted millions out of poverty, and it has developed a set of robust, and improving institutions along the way.
The extent to which follow-on pharmaceutical innovations should be protectable by patents is hotly debated amongst the public health and IP community in Geneva. But are fears that follow-on patents simply extend indefinitely, or “evergreening,” medicine patents justified?
Separating the cost of biopharmaceutical research and development from the final market price of medicines would misalign incentives, raise bureaucratic costs, and limit innovation.